Don't fall for the 'next best action' trap

OKRA 15 September, 2020. London, UK.
OKRA has announced a new, free webinar called 'Why Next Best Action is not enough', a panel will discuss the urgent need to move beyond the current trend of adding simplistic or 'dumb' AI tools to sales force dashboards.

These AI tools make sense for managers - they are very easy to apply, inexpensive, and give reps an enhanced view of the market - but in the medium-to-long term will likely cause more harm than good.

During the webinar we will discuss why we must immediately take more care when installing these systems. In particular, we must avoid three common traits:

Autocratic

Most of us would recoil in fear if we were told that our next manager was going to be an autocrat. We would far rather a boss who used carrots rather than sticks to motivate his/her workforce. We would value empathy and flexibility in our leadership: ultimately it's preferable to have someone we want to work for.

Yet the next best action systems are very much the opposite. They bark out single-line instructions that come with very little nuance. Even if they are right, it won't take long for us to want to 'rage against the machine'.

Unexplained

The vast majority of AI systems being deployed are 'black box'. And there's a very good reason for that: AI systems learn as they go, and it eventually becomes more and more difficult to understand their reasoning. In fact, the more sophisticated and intelligent the AI, the harder it is to explain the decisions it makes.

But like the autocratic manager, we quickly lose trust and respect if we cannot break down our actions or decisions into rational arguments.

Dumb

There are different grades of AI. Many of the systems being deployed currently are 'rules-based systems' - where an inferior artificial intelligence is given guidelines and parameters to work with, in order that it can figure out what it needs to.

And you would think that by setting up such a scenario, you would be helping the AI, a little bit like adding stabilisers onto a child’s bicycle to stop them falling over.

However it is also easy to understand that nobody would ever compete in the Tour de France with stabilisers on their bike. These stabilisers would stop you ever from becoming an elite cyclist, and rules-based systems are similarly unable to become as smart as we require.

Non-rules based systems, or 'deep' AI, are far more difficult to create. Typically, such systems are not even told the rules of the game when they start playing. However they quickly supersede their counterparts and become insightful - and useful.

Ultimately, it’s about trust

Our industry has experienced countless 'digital transformation' initiatives that have failed to get off the ground. Often that's not because of the sophistication of the technology but because of the lack of belief or trust in the system. Next best action systems are no different in this regard.

Join this free webinar to witness the solution - what is possible - and how to avoid these common pitfalls that could otherwise result in a lot of wasted money, morale and a lack of interest in engaging with future solutions.

For durther information and to register, please visit:
https://okra.ai/webinar

About OKRA

At OKRA we are fostering a new generation of ArtificiaI Intelligence (AI) solutions that support the healthcare ecosystem. Our solutions are implemented by top pharma companies throughout the product pipeline to empower employees in decision making around complex problems.

OKRA's AI solutions are translating large clinical, scientific and commercial data sets into actionable insights that employees in life science companies can easily query at their desks or whilst on the move.

We believe that for AI to truly empower people, the insights presented must be explainable and instil confidence when driving action. Our suite of products have been built in partnership with top life science companies, with a focus on empowering the people to take action.

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...